Publication
Inhibition of the atypical kinase WNK1 as a therapeutic strategy in TAL-related T-cell acute lymphoblastic leukemia.
Anna Montanaro, Gregorio Monica, Raffaella Zamponi, Anna D'Antuono, Alice Andreani, Pietro Andrei, Angela H Su, Alessia Ciringione, Gabriella Sammarelli, Giannalisa Todaro, Roberto Rosati, Roberta La Starza, Cristina Mecucci, Loredana Elia, Andrea Gherli, Federica Vento, Elisa Simoncini, Bruno Lorusso, Costanza Anna Maria Lagrasta, Mariateresa Giaimo, Luca Pagliaro, Matteo Marchesini, Connie R Jimenez, Federico Quaini, Kimberly Stegmaier, Giovanni Roti
- Source
- PubMed
- Retrieved
- Sep 19, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260919-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Driver mutations in T-cell acute lymphoblastic leukemia (T-ALL) rarely affect druggable kinases. However, these kinases can be aberrantly activated or repressed as secondary oncogenic events. Thus, integrating unbiased phosphoproteomics with genomic approaches may offer novel opportunities for…
Read on PubMedLinked entities
Linked entities (3)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 2
- trialNCT03117751registry_reference1.00
- trialNCT05745714registry_reference1.00
Candidate 1
- cancerLeukemiadictionary0.60
Registered trialsNCT03117751NCT05745714
Curated evidence
Evidence citing this paper (0)
Data not yet available